CorMedix Inc

詳細情報 CorMedix Inc 企業名

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

企業情報

企業コードCRMD

会社名CorMedix Inc

上場日Mar 25, 2010

設立日2006

最高経営責任者「CEO」Mr. Joseph Todisco

従業員数64

証券種類Ordinary Share

決算期末Mar 25

本社所在地300 Connell Drive

都市BERKELEY HEIGHTS

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号07922

電話番号19085179500

ウェブサイトhttps://cormedix.com/

企業コードCRMD

上場日Mar 25, 2010

設立日2006

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Joseph Todisco

Chief Executive Officer, Director

323.43K

-2.01%

Mr. Steven W. Lefkowitz

Independent Director

127.65K

-3.77%

Ms. Janet M. Dillione

Independent Director

53.47K

-31.86%

Ms. Erin Mistry

Executive Vice President, Chief Commercial Officer

29.12K

-54.14%

Mr. Robert Stewart

Independent Director

11.00K

-69.44%

Mr. Dan Ferry

IR Contact Officer

--

Dr. Alan William Dunton, M.D.

Independent Director

--

Ms. Elizabeth (Liz) Massonhurlburt

Executive Vice President, Chief Clinical Strategy and Operations Officer

--

Dr. Matthew T. (Matt) David, M.D.

Chief Financial Officer, Executive Vice President

--

Ms. Beth Zelnick Kaufman

Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Joseph Todisco

Chief Executive Officer, Director

323.43K

-2.01%

Mr. Steven W. Lefkowitz

Independent Director

127.65K

-3.77%

Ms. Janet M. Dillione

Independent Director

53.47K

-31.86%

Ms. Erin Mistry

Executive Vice President, Chief Commercial Officer

29.12K

-54.14%

Mr. Robert Stewart

Independent Director

11.00K

-69.44%

Mr. Dan Ferry

IR Contact Officer

--

収益内訳

FY2025Q1

FY2024

データなし

地域別USD

会社名

収益

比率

United States

39.08M

0.00%

事業別

地域別

データなし

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

5.80%

The Vanguard Group, Inc.

4.89%

Elliott Management Corporation

3.29%

State Street Global Advisors (US)

2.07%

Geode Capital Management, L.L.C.

1.93%

Other

82.02%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

5.80%

The Vanguard Group, Inc.

4.89%

Elliott Management Corporation

3.29%

State Street Global Advisors (US)

2.07%

Geode Capital Management, L.L.C.

1.93%

Other

82.02%

種類

株主統計

比率

Investment Advisor

12.60%

Investment Advisor/Hedge Fund

12.43%

Hedge Fund

5.19%

Research Firm

1.46%

Sovereign Wealth Fund

1.27%

Individual Investor

1.08%

Pension Fund

0.41%

Bank and Trust

0.28%

Venture Capital

0.05%

Other

65.24%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

271

25.90M

34.85%

-8.20M

2025Q1

281

29.73M

44.27%

-179.25K

2024Q4

252

24.74M

40.82%

-30.08K

2024Q3

228

19.79M

34.25%

-1.78M

2024Q2

217

17.74M

32.28%

-4.09M

2024Q1

218

17.92M

32.60%

-5.73M

2023Q4

217

19.38M

35.35%

-2.82M

2023Q3

208

18.46M

33.68%

-3.54M

2023Q2

197

19.74M

38.10%

+6.18M

2023Q1

190

11.28M

25.34%

-2.76M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

4.31M

5.8%

+109.81K

+2.61%

Mar 31, 2025

The Vanguard Group, Inc.

3.63M

4.89%

+255.97K

+7.58%

Mar 31, 2025

Elliott Management Corporation

2.44M

3.29%

-426.07K

-14.84%

Mar 31, 2025

State Street Global Advisors (US)

1.54M

2.07%

+85.97K

+5.92%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.43M

1.93%

+40.10K

+2.88%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

940.59K

1.27%

+940.59K

--

Dec 31, 2024

UBS Financial Services, Inc.

602.53K

0.81%

+222.67K

+58.62%

Mar 31, 2025

Morgan Stanley & Co. LLC

587.83K

0.79%

+304.71K

+107.63%

Mar 31, 2025

Palisades Investment Partners, LLC

358.97K

0.48%

-5.05K

-1.39%

Mar 31, 2025

Northern Trust Investments, Inc.

498.68K

0.67%

-12.22K

-2.39%

Mar 31, 2025

詳細を見る

10.980USD

CorMedix Inc

10.980

概要

企業名

金融